Ranitidine: Difference between revisions
Elcatracho (talk | contribs) |
|||
| (11 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: H2 | *Type: [[H2 blocker]] | ||
*Dosage Forms: | *Dosage Forms: 75mg, 150mg, 300mg | ||
*Common Trade Names: Zantac | *Common Trade Names: Zantac | ||
==Adult Dosing== | ==Adult Dosing== | ||
GERD: | GERD: 150mg PO BID | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
GERD: 5- | GERD: 5-10mg/kg/day PO BID | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: | *Lactation: Probably Safe | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult: CrCl < 50: 150mg Qday; CrCl < 10: 75 -150mg Qday; HD: give dose after dialysis | ||
**Pediatric | **Pediatric: CrCl < 10-50: decrease dose 50%; CrCl< 10: decrease dose 75%; HD: Give dose after dialysis | ||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult: Not defined | ||
**Pediatric | **Pediatric: not defined | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Porphyria | |||
*Caution if impairment of liver or kidneys | |||
*Caution in chronic pulmonary disease | |||
*Caution if diabetes mellitus | |||
*Caution if immunocompromised | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Thrombocytopenia | |||
*Hepatotoxicity | |||
*[[Pneumonia]] | |||
===Common=== | ===Common=== | ||
*Nausea/vomiting/diarrhea | |||
*Fatigue | |||
*Headache | |||
*Rash | |||
*Myalgia | |||
*Xerostomia | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 2-3 hr, Renal impairment: 5 hr | ||
*Metabolism: | *Metabolism: Liver | ||
*Excretion: | *Excretion: Urine, Feces | ||
*Mechanism of Action: | *Mechanism of Action: H2 blocker | ||
==See Also== | ==See Also== | ||
==References== | |||
<references/> | <references/> | ||
[[Category: | |||
[[Category:Pharmacology]] | |||
Latest revision as of 22:30, 7 March 2021
General
- Type: H2 blocker
- Dosage Forms: 75mg, 150mg, 300mg
- Common Trade Names: Zantac
Adult Dosing
GERD: 150mg PO BID
Pediatric Dosing
GERD: 5-10mg/kg/day PO BID
Special Populations
- Pregnancy Rating: B
- Lactation: Probably Safe
- Renal Dosing
- Adult: CrCl < 50: 150mg Qday; CrCl < 10: 75 -150mg Qday; HD: give dose after dialysis
- Pediatric: CrCl < 10-50: decrease dose 50%; CrCl< 10: decrease dose 75%; HD: Give dose after dialysis
- Hepatic Dosing
- Adult: Not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
- Porphyria
- Caution if impairment of liver or kidneys
- Caution in chronic pulmonary disease
- Caution if diabetes mellitus
- Caution if immunocompromised
Adverse Reactions
Serious
- Thrombocytopenia
- Hepatotoxicity
- Pneumonia
Common
- Nausea/vomiting/diarrhea
- Fatigue
- Headache
- Rash
- Myalgia
- Xerostomia
Pharmacology
- Half-life: 2-3 hr, Renal impairment: 5 hr
- Metabolism: Liver
- Excretion: Urine, Feces
- Mechanism of Action: H2 blocker